Description:FIELD OF THE INVENTION

The present invention relates to the field of numerical methods, computational pharmacology, and rural healthcare technology, with a specific focus on developing a generalized iterative model for solving transcendental nonlinear equations to enhance drug dosage optimization. This invention lies at the intersection of applied mathematics, biomedical engineering, and digital healthcare systems, aiming to improve the accuracy and efficiency of drug administration protocols, particularly in underserved and resource-limited rural areas. Traditional dosage determination often relies on simplified models or fixed dosage guidelines, which may not accommodate the nonlinear, patient-specific dynamics of drug absorption, distribution, metabolism, and excretion. The proposed invention introduces an advanced iterative computational framework capable of solving complex, multivariable, transcendental equations that model these dynamics more accurately. It incorporates adaptive convergence techniques and individual patient parameters to personalize dosage calculations, thus significantly improving therapeutic outcomes. Moreover, the invention is adaptable for integration into digital healthcare platforms and mobile applications, empowering frontline healthcare workers in rural settings to perform advanced pharmacokinetic analysis without needing access to sophisticated medical infrastructure. This invention not only broadens the utility of iterative numerical methods in biomedical applications but also directly addresses challenges in healthcare equity, by enabling precise, algorithm-driven medical decision-making where traditional healthcare delivery models fall short. The field of invention encompasses numerical algorithm design, clinical decision support systems, computational medicine, and health informatics, providing a practical and impactful tool that bridges the gap between advanced mathematical modeling and real-world clinical application in low-resource environments.

Background of the proposed invention:

The background of the proposed invention, titled “A Generalized Iterative Model for Transcendental Nonlinear Equations to Advance Drug Dosage Optimization in Rural Healthcare,” lies in the convergence of numerical methods, computational modeling, and healthcare delivery systems, particularly in addressing the limitations of traditional pharmacological approaches in rural settings. Drug dosage optimization is a critical aspect of patient care, ensuring that medications are administered in a manner that maximizes therapeutic benefit while minimizing side effects and toxicity. However, in many rural and resource-constrained environments, this optimization process is fraught with challenges due to limited access to qualified medical professionals, diagnostic tools, real-time monitoring systems, and tailored drug response data. Traditionally, drug dosages are derived from standard population-based models or empirical heuristics, which assume linear pharmacokinetics and uniform metabolic responses across patients. These models often overlook the intricate nonlinearities present in drug absorption, distribution, metabolism, and excretion (ADME), especially when patients present with co-morbid conditions, polypharmacy situations, or genetic and environmental variabilities. In reality, drug behavior in the human body is governed by complex transcendental nonlinear equations, which describe processes such as enzyme saturation, nonlinear clearance, delayed absorption, and feedback-regulated metabolic pathways. These equations, which involve exponential, logarithmic, or trigonometric functions combined with multiple variables, are inherently difficult to solve using conventional closed-form analytical techniques, especially in the presence of uncertain or incomplete data. Iterative numerical methods, such as the Newton-Raphson method, bisection method, and secant method, offer computational strategies to approximate solutions to these equations, but standard approaches often suffer from convergence issues, sensitivity to initial guesses, and inflexibility in handling patient-specific variability. In rural healthcare settings, where computational resources are limited and healthcare providers may lack extensive training in mathematical modeling, there is a dire need for a robust, adaptable, and user-friendly computational framework that can handle the mathematical complexity of dosage calculations while being deployable on low-power, mobile platforms. The proposed invention addresses this gap by introducing a generalized iterative model that enhances classical root-finding methods through the integration of adaptive step control, parameter sensitivity analysis, and convergence acceleration algorithms. This model is capable of dynamically adjusting its iteration strategy based on real-time feedback and variable interdependencies, ensuring faster and more accurate convergence to biologically relevant solutions. The innovation lies not only in the mathematical refinement of the iterative scheme but also in its embedding within a patient-centric, algorithmic platform that accepts vital parameters—such as age, weight, renal function, hepatic clearance, genetic markers, and concurrent medications—as inputs to refine the model’s behavior. Furthermore, the model is designed to accommodate real-world constraints such as intermittent patient adherence, fluctuating vital signs, and variations in environmental conditions that may influence drug metabolism. It employs robust error correction mechanisms and predictive modeling to compensate for incomplete or noisy data, a common issue in rural clinical environments. The model can also simulate various dosing scenarios and predict concentration-time profiles to help healthcare workers visualize and select optimal regimens, even for drugs with narrow therapeutic indices. A major advantage of this invention is its modularity and compatibility with existing mHealth infrastructure, allowing integration with wearable devices, mobile health apps, and digital diagnostic platforms. By transforming complex numerical methods into a practical, actionable tool, the invention bridges the longstanding divide between theoretical pharmacokinetics and real-world clinical practice. It empowers community health workers, pharmacists, and rural clinicians with decision-support capabilities that traditionally required expert pharmacological knowledge and sophisticated software. This innovation also has potential implications for public health policy, enabling the development of region-specific dosage guidelines that reflect local population health data and therapeutic outcomes. Moreover, by ensuring that dosages are tailored, effective, and safe, the invention contributes to improved drug compliance, reduced incidence of adverse drug reactions, and more efficient use of limited medical resources. In the broader context of global health, the proposed iterative model represents a significant advancement in computational medicine, demonstrating how algorithmic thinking and mathematical precision can directly impact patient outcomes in underserved areas. As the healthcare landscape increasingly embraces digital transformation, this invention aligns with the goals of precision medicine, universal health coverage, and equitable access to care. It supports a paradigm shift from reactive, generalized treatment protocols to proactive, individualized healthcare strategies that are responsive to both clinical complexity and logistical constraints. In conclusion, the background of this invention underscores a critical unmet need in rural healthcare and offers a scientifically rigorous, technologically feasible, and socially impactful solution through the development of a generalized iterative model for transcendental nonlinear equations tailored to optimize drug dosage.

Summary of the proposed invention:

The proposed invention, titled “A Generalized Iterative Model for Transcendental Nonlinear Equations to Advance Drug Dosage Optimization in Rural Healthcare,” presents a transformative solution to a longstanding issue in clinical pharmacology—how to ensure accurate, personalized drug dosage in settings constrained by limited medical infrastructure and computational resources. In many rural and underserved regions, drug administration follows generalized dosage guidelines that often fail to reflect the pharmacokinetic and pharmacodynamic complexities inherent to individual patients. These standard models, typically linear or empirical, do not account for the highly nonlinear interactions of physiological parameters such as age, body weight, renal and hepatic function, genetic polymorphisms, disease co-morbidities, and drug-drug interactions. These interactions are best described using transcendental nonlinear equations that represent real-world phenomena such as delayed drug absorption, enzyme-saturated metabolism, feedback-regulated elimination, and tissue compartmentalization. Solving such equations requires numerical methods, particularly iterative techniques, as closed-form solutions are either impossible or unreliable. However, classical iterative methods such as Newton-Raphson, secant, or bisection techniques, though mathematically rigorous, are not tailored for the dynamic, multidimensional, and often noisy data encountered in real-time drug dosing in rural healthcare environments. They require careful tuning, suffer from slow convergence or divergence near singularities, and are not adaptable to individual patient variability or incomplete data inputs. The proposed invention introduces a generalized iterative model that expands upon these classical methods by integrating adaptive convergence control, parameter sensitivity feedback, error correction mechanisms, and modularity to handle a wider class of transcendental nonlinear functions and patient-specific variables. The model leverages adaptive step-size algorithms that dynamically adjust iteration strategies based on convergence trends, allowing for faster and more accurate root estimation. Importantly, the model incorporates built-in resilience to data uncertainty by applying intelligent smoothing functions and data interpolation when inputs are missing or irregular—an essential feature for rural and low-resource healthcare environments where diagnostic tools and monitoring may be limited or infrequent. One of the central innovations lies in the ability of the model to handle multivariate systems of equations, enabling it to simulate and solve entire pharmacokinetic models that include multiple drugs and interacting physiological systems. This becomes especially important in treating chronic conditions such as diabetes, hypertension, tuberculosis, or HIV/AIDS, where patients are often on multiple medications. The proposed model is not designed for use solely by experts in mathematics or medicine; instead, it is engineered for seamless integration into mobile health (mHealth) applications and decision-support systems that can be used by community health workers or general practitioners with limited formal training in advanced pharmacology. By simply inputting a few patient-specific parameters—such as age, weight, basic vitals, and known medical conditions—the system can apply the model to recommend an optimized dosage that balances efficacy and safety. Furthermore, it can simulate drug concentration-time profiles to visualize therapeutic windows, thereby helping practitioners avoid subtherapeutic doses or toxic levels. The model can also account for external factors such as missed doses or irregular intake, offering dosage adjustment suggestions and highlighting the risks of non-adherence. Another significant aspect of this invention is its modular architecture, allowing it to interface with other software systems such as electronic health records (EHR), wearable monitoring devices, and AI-based diagnostic platforms. It supports both real-time and batch-mode computation, making it suitable for both immediate clinical decisions and retrospective analysis for public health data modeling. In terms of computational load, the model is optimized to run on low-power devices such as smartphones or tablets, using efficient algorithmic logic and minimal memory overhead—further enhancing its utility in rural settings where high-end computing resources are not available. The algorithm can also be deployed via cloud platforms for centralized monitoring, enabling data aggregation for regional health authorities to assess patterns in drug efficacy, adherence, and adverse events. In validation studies, the model has demonstrated superior performance over standard empirical dosage calculators, particularly in terms of convergence speed, root accuracy, and adaptability to various patient profiles. Simulation-based testing using both synthetic datasets and anonymized clinical records from rural hospitals has confirmed the model’s robustness and clinical relevance. For example, in complex pharmacokinetic models involving first-order absorption with Michaelis-Menten elimination, the proposed model successfully estimated optimal dosing intervals and amounts within clinically acceptable error margins. From a broader perspective, this invention contributes significantly to the evolving field of personalized medicine, particularly in the context of health equity. By enabling accurate, patient-specific dosage recommendations in low-resource environments, the invention addresses the global health challenge of unequal access to advanced medical decision-making tools. It offers an algorithmic, data-driven alternative to trial-and-error dosing and blanket treatment protocols that often lead to poor outcomes in rural populations. Furthermore, this system can be instrumental in guiding medication regimens during public health emergencies, such as pandemics or disease outbreaks, where rapid deployment of customized care protocols is essential. From a technological standpoint, this invention aligns with current trends in smart healthcare and artificial intelligence by providing a model that is both mathematically sophisticated and practically deployable. It opens avenues for further enhancements, such as integration with machine learning algorithms to refine iteration parameters or predict patient outcomes based on historical data. Additionally, the framework can be generalized to other domains involving transcendental nonlinear equations beyond pharmacology, such as epidemiological modeling, biochemical pathway analysis, and personalized nutrition planning. In conclusion, the proposed invention represents a holistic, interdisciplinary solution that synthesizes advanced mathematics, clinical pharmacology, and digital health technology to solve a real-world problem of immense significance. It transforms the traditionally expert-dependent process of dosage calculation into an accessible, automated, and reliable process, especially suited for rural and underserved areas where the burden of disease is often the highest and access to specialized care is limited. By empowering local healthcare workers with a scientifically validated tool that enhances patient safety, therapeutic precision, and treatment adherence, this invention has the potential to revolutionize rural healthcare delivery and set a new standard for algorithmically guided medical interventions in low-resource settings.
Brief description of the proposed invention:

The proposed invention, “A Generalized Iterative Model for Transcendental Nonlinear Equations to Advance Drug Dosage Optimization in Rural Healthcare,” offers a novel, mathematically grounded, and clinically applicable framework that revolutionizes the approach to drug dosing in underserved regions by addressing the fundamental computational challenges of solving complex nonlinear pharmacokinetic equations. This invention is built upon the premise that drug behavior within the human body—encompassing absorption, distribution, metabolism, and excretion (ADME)—follows nonlinear and often transcendental relationships that are difficult to solve using traditional linear models or simplistic empirical formulas typically employed in rural healthcare environments. Conventional methods often disregard the intricate interplay between multiple physiological and environmental variables that affect individual patient responses to medication, leading to either subtherapeutic dosing or adverse drug reactions. The invention introduces a comprehensive iterative computational model that extends beyond classical root-finding techniques such as Newton-Raphson, bisection, or secant methods, by incorporating adaptive algorithms, convergence correction, and multidimensional input mapping to address the challenges posed by transcendental nonlinear equations in pharmacology. The model is capable of dynamically recalibrating its iterative steps in response to the sensitivity of input variables, error trends, and rate of convergence, making it uniquely suited for real-time and patient-specific dose calculations. It accepts patient-centric data—such as age, weight, gender, renal and hepatic function indices, disease conditions, and concurrent drug usage—as primary inputs and integrates them into a system of nonlinear equations that model drug concentration over time, metabolic saturation thresholds, therapeutic windows, and side effect profiles. These equations often contain logarithmic, exponential, and trigonometric components, making them analytically intractable and necessitating iterative numerical solutions. The invention's core lies in its generalized iterative engine, which not only computes roots with high precision but also allows for error correction based on predicted deviations in pharmacokinetic response. A key feature of the model is its resilience to missing, incomplete, or noisy data, which is a common scenario in rural and low-resource healthcare environments. Through the use of built-in statistical interpolation, confidence weighting, and smoothing algorithms, the model continues to provide safe and clinically reliable dosage recommendations even when full datasets are unavailable. Moreover, the invention is designed to be modular and interoperable, allowing seamless integration with mobile health (mHealth) platforms, wearable biosensors, electronic health records (EHRs), and other telemedicine systems. This enables community health workers and general practitioners with minimal technical training to utilize advanced pharmacological modeling tools at the point of care using handheld devices. The model provides not just dosage outputs but also graphical visualizations of predicted drug concentration-time curves, duration within therapeutic windows, and projected efficacy based on patient adherence or physiological changes. The algorithm is computationally optimized to operate on low-power devices, making it suitable for deployment in remote areas without sophisticated computational infrastructure. It is also designed for both offline and online use, with optional cloud synchronization for patient data tracking, central database updates, and longitudinal studies on drug performance in specific populations. The model’s functionality extends to complex drug regimens involving multiple pharmacological agents, accounting for synergistic or antagonistic interactions, cumulative toxicity, and time-dependent dosing effects. It supports both first-order and nonlinear Michaelis-Menten kinetic models, enabling it to cater to a wide range of drugs including antibiotics, antivirals, antidiabetics, antituberculosis agents, and cardiovascular medications. In clinical trials and computational simulations, the model demonstrated rapid convergence, reduced root-mean-square error (RMSE), and improved therapeutic accuracy compared to conventional dosing calculators. For instance, when applied to patient datasets involving nonlinear clearance rates and delayed-release formulations, the model successfully optimized dosage intervals and quantities with significantly better precision, aligning predicted plasma concentrations more closely with actual observed values. In addition to point-of-care decision support, the model can be utilized by health policy makers and researchers to generate population-level dosage trends, identify patterns in drug inefficacy or adverse reactions, and formulate context-specific dosage guidelines. It holds potential for predictive analytics by enabling simulations that assess the impact of varying drug dosages across diverse patient scenarios, thus aiding in clinical trials, pharmacovigilance, and personalized medicine development. From a technical perspective, the model supports plug-and-play modules where new pharmacokinetic models can be incorporated without overhauling the core algorithm, making it extensible and future-proof. It also includes safety features such as upper and lower bound constraints, automatic alerts for toxic dose thresholds, and integration with drug interaction databases to ensure regulatory compliance and clinical safety. Furthermore, the invention fosters patient engagement by offering simplified dosage explanations and alerts through user-friendly interfaces in local languages, increasing trust and adherence in medication regimens. From an innovation standpoint, this invention uniquely bridges the gap between high-level computational pharmacology and grassroots-level healthcare delivery. By abstracting complex mathematical computations into an accessible, user-friendly tool, it empowers frontline healthcare providers with precision medicine capabilities that are typically reserved for specialized urban healthcare centers. Its versatility across drug classes, adaptability to various physiological and demographic profiles, and resilience in data-sparse conditions make it a critical innovation for addressing global healthcare inequalities. Moreover, the model is well-suited to support public health initiatives such as antimicrobial stewardship programs, mass drug administration campaigns, and chronic disease management protocols in developing nations. With potential applications extending to emergency dosing in pandemics, neonatal and geriatric care, and personalized therapy in genomically diverse populations, this invention represents a paradigm shift in how dosage calculations are performed and delivered. By leveraging numerical mathematics to solve real-world clinical problems, the invention sets a new benchmark for interdisciplinary innovation in healthcare technology. It enables scalable, intelligent, and decentralized decision-making, thereby improving treatment outcomes, reducing hospitalization due to drug errors, and optimizing the use of limited pharmaceutical resources. Overall, this brief description outlines how the proposed invention addresses a critical healthcare challenge using a robust, adaptive, and clinically validated computational solution that is ready for real-world deployment, particularly in the rural healthcare ecosystems where it is needed the most.
, Claims:We Claim:

1. A method for calculating optimized drug dosage comprising the steps of:
i. Receiving patient-specific input parameters including at least age, weight, renal function, hepatic function, and current medications;
ii. Formulating a transcendental nonlinear equation that models drug pharmacokinetics based on said inputs; and
iii. Solving said equation using a generalized iterative model with adaptive convergence to determine an optimal dosage recommendation.

2. The method of claim 1, wherein the generalized iterative model comprises an enhanced root-finding algorithm that includes dynamic step-size control, convergence threshold adjustment, and error correction based on iteration feedback.

3. The method of claim 1, wherein the model is configured to accept incomplete or noisy input data and compensates by applying statistical smoothing, data interpolation, and confidence weighting to maintain result integrity.

4. A system for drug dosage optimization in rural healthcare comprising:
i. A mobile computing device,
ii. A software module implementing the generalized iterative model,
iii. A patient data input interface,
iv. A display unit for presenting optimized dosage recommendations and pharmacokinetic profiles.

5. The system of claim 4, wherein the software module is configured to handle multi-drug regimens and models pharmacological interactions using a set of interdependent transcendental nonlinear equations solved concurrently.

6. The method of claim 1, wherein the dosage optimization includes visualization of concentration-time curves, therapeutic windows, and alerts for potential underdosing or overdosing conditions.

7. The system of claim 4, wherein the mobile computing device is a low-power, offline-capable smartphone or tablet operable in remote or resource-limited environments.

8. The method of claim 1, further comprising real-time integration with wearable devices or sensors to adjust dosage recommendations dynamically based on continuous monitoring of physiological parameters.

9. A non-transitory computer-readable medium storing instructions that, when executed by a processor, cause a device to perform the method steps of claim 1, including formulation of patient-specific nonlinear equations and solution via the generalized iterative model.

10. The method of claim 1, wherein the model further enables batch-mode simulations for health authorities to evaluate population-wide dosage strategies, assess risk trends, and develop data-driven public health policies.